| Mark E Fahey, MD | |
|
3334 Capital Medical Blvd, Suite 400, Tallahassee, FL 32308-4470 | |
| (850) 877-8174 | |
| (850) 877-5636 |
| Full Name | Mark E Fahey |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 37 Years |
| Location | 3334 Capital Medical Blvd, Tallahassee, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194728956 | NPI | - | NPPES |
| 000500728C | Medicaid | GA | |
| 370237500 | Medicaid | FL | |
| 000500728D | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | ME53578 (Florida) | Primary |
| 207X00000X | Orthopaedic Surgery | 039786 (Georgia) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tallahassee Orthopedic Clinic Iii Pl | 4284532755 | 100 |
| Tallahassee Orthopedic Clinic Iii Pl | 4284532755 | 100 |
News Archive
Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.
Mayo Clinic ranked near the top of the 23rd U.S. News & World Report annual America's Best Hospital list, earning the No. 3 overall spot on its "Best Hospitals" list. Mayo Clinic in Rochester also was rated best in the nation in three clinical areas - gynecology, diabetes and endocrinology, and gastroenterology.
An open letter with signatories including AusBiotech, Medicines Australia, Research Australia, the Walter and Eliza Hall Institute of Medical Research and Foursight has been addressed to members of the Australian Parliament, urging them to reject the ‘Patent Amendment (Human Genes and Biological Materials) Bill 2010' as it misses the point on patient access and research exemption.
Study findings suggest that use of selective serotonin reuptake inhibitors during pregnancy does not pose any increased infant mortality risk.
Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.
› Verified 5 days ago
| Entity Name | Tallahassee Orthopedic Clinic Iii Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778050 PECOS PAC ID: 4284532755 Enrollment ID: O20031222000343 |
News Archive
Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.
Mayo Clinic ranked near the top of the 23rd U.S. News & World Report annual America's Best Hospital list, earning the No. 3 overall spot on its "Best Hospitals" list. Mayo Clinic in Rochester also was rated best in the nation in three clinical areas - gynecology, diabetes and endocrinology, and gastroenterology.
An open letter with signatories including AusBiotech, Medicines Australia, Research Australia, the Walter and Eliza Hall Institute of Medical Research and Foursight has been addressed to members of the Australian Parliament, urging them to reject the ‘Patent Amendment (Human Genes and Biological Materials) Bill 2010' as it misses the point on patient access and research exemption.
Study findings suggest that use of selective serotonin reuptake inhibitors during pregnancy does not pose any increased infant mortality risk.
Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark E Fahey, MD 3334 Capital Medical Blvd, Ste. 400, Tallahassee, FL 32308-4470 Ph: (850) 877-8174 | Mark E Fahey, MD 3334 Capital Medical Blvd, Suite 400, Tallahassee, FL 32308-4470 Ph: (850) 877-8174 |
News Archive
Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.
Mayo Clinic ranked near the top of the 23rd U.S. News & World Report annual America's Best Hospital list, earning the No. 3 overall spot on its "Best Hospitals" list. Mayo Clinic in Rochester also was rated best in the nation in three clinical areas - gynecology, diabetes and endocrinology, and gastroenterology.
An open letter with signatories including AusBiotech, Medicines Australia, Research Australia, the Walter and Eliza Hall Institute of Medical Research and Foursight has been addressed to members of the Australian Parliament, urging them to reject the ‘Patent Amendment (Human Genes and Biological Materials) Bill 2010' as it misses the point on patient access and research exemption.
Study findings suggest that use of selective serotonin reuptake inhibitors during pregnancy does not pose any increased infant mortality risk.
Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.
› Verified 5 days ago
David A Bellamy, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3334 Capital Medical Blvd, Ste. 400, Tallahassee, FL 32308 Phone: 850-877-8174 Fax: 850-877-5636 | |
Thomas C Haney, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3334 Capital Medical Blvd Ste 400, Tallahassee, FL 32308 Phone: 850-877-8174 Fax: 850-877-5636 | |
Charles Jackson Holland, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2390 Phillips Road, Tallahassee, FL 32308 Phone: 850-487-2604 Fax: 850-922-2123 | |
David Antonio Alvarez, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3334 Capital Medical Blvd Ste 400, Tallahassee, FL 32308 Phone: 850-877-8174 Fax: 850-877-5636 | |
Dr. Ryan Christopher Price, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1401 Centerville Rd Ste 710, Tallahassee, FL 32308 Phone: 850-877-8174 Fax: 850-877-5636 | |
Adam Almaguer, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3334 Capital Medical Blvd Ste 400, Tallahassee, FL 32308 Phone: 508-778-1748 |